COPING WITH ANTIMICROBIAL RESISTANCE

Transcription

1 JANUARY 2018 COPING WITH ANTIMICROBIAL RESISTANCE REPORT

2 2 Friends of Europe January 2018 This is truly a global problem that can only be addressed by working together across the planet Tamsin Rose Senior Fellow at Friends of Europe ANTIMICROBIAL RESISTANCE - TIME TO BE CONCRETE Antimicrobial resistance (AMR) has become a political priority: from the G20 to the European Union, governments are committed to working together. Strategy documents have been drafted, and public, private as well as research sectors have developed partnerships. It is now time for concrete action and we all have a part to play. That was the conclusion of experts speaking at Coping with Antimicrobial Resistance, a Friends of Europe Café Crossfire event on 23 January. An initial discussion led by Friends of Europe in November 2016 on Policies to counter risks to global health already identified AMR as one of the current deadliest global threats on the planet, and called for stronger political commitment and multisector cooperation to counter this rising risk. Some 50,000 people die every year in the EU and the United States from antimicrobial resistant infections, a figure that could rise to 10 million by 2050 if the problem is not properly addressed. This is truly a global problem that can only be addressed by working together across the planet, said moderator Tamsin Rose, a Senior Fellow at Friends of Europe. We should be very worried Francesca Colombo Head of the OECD Health Division HOW DID WE GET HERE? One of the main causes of AMR is the misuse of antibiotics. Particularly the systematic and excessive use of antibiotics, said Cristian-Silviu Bușoi, Member of the European Parliament Committee on Industry, Research and Energy. We should be very worried, said Francesca Colombo, Head of the OECD Health Division. Being infected with resistant bacteria rather than non-resistant bacteria doubles the probability of death. It also massively increases costs for European healthcare systems, currently estimated at 6.2 billion a year. CUTTING BACK ON ANTIBIOTIC USE Though some EU member states have cut back on antibiotic use, others have not, said Charles Price, Head of AMR at the Unit for Crisis management and preparedness in health in the European Commission Directorate-General for Health and Food Safety. The EU has coordinated efforts to curb misuse, but in 2015 resistance to last-line antibiotics continued to increase. In Europe today, 50% of antibiotic use in human health is inappropriate. In animal health, the figure is even higher. The use of antibiotics as animal growth promoters has been banned in the EU since 2007, unlike in some of our trading partners. There has also been a major programme of better animal welfare to prevent infections.

3 Coping with antimicrobial resistance Report 3 However, antibiotics are still used preventatively for animal livestock in some countries and proposed EU legislation to stop this has been stuck in the European Council and Parliament since However, antibiotics are still used preventatively for animal livestock in some countries and proposed EU legislation to stop this has been stuck in the European Council and Parliament since GETTING THE BASICS RIGHT: DIAGNOSTICS, HYGIENE AND VACCINATION Currently, general spectrum antibiotics are prescribed in healthcare even if they might not actually benefit the patient. We need faster, more appropriate diagnostic tools to make sure that antibiotics are used for specific infections and only used when necessary, said Jean Lang, Associate Vice President at Sanofi Pasteur Research & Development. In Europe today, 50% of antibiotic use in human health is inappropriate. In animal health, the figure is even higher Charles Price Head of AMR at the Unit for Crisis management and preparedness in health in the European Commission Directorate- General for Health and Food Safety It is also about good sanitation and improving hygiene practices, particularly in hospitals, said Bușoi. Such basic measures could lead to dramatic improvements, said Colombo. These interventions are indeed extremely cost effective. If we upscale the stewardship interventions in 80% of the hospitals in Europe and the largest OECD countries, we halve the probability of dying because of infection. This lesson applies to developing countries and to other diseases too, said Lang. Take the example of Ebola. Of course an effective vaccine is needed. But it was the lack of functioning healthcare systems in the countries concerned that turned the outbreak into an epidemic. THE IMPORTANCE OF VACCINES While vaccines and antibiotics are essential medical assets that must be used with care, AMR has not been helped by the drop in vaccination coverage across Europe. Lang said. One of the weapons against AMR is vaccines. For example, reaching flu vaccination targets would result in fewer bacterial infections that often accompany flu, thereby reducing the need for antibiotics. Social media campaigns against immunisation have badly damaged public trust, and public health efforts should take on this issue, said Bușoi. We have to tackle campaigns against vaccination in all countries particularly in Central and Eastern European countries. In Romania, I see a lot of these messages online and I try to be active in these debates and provide the real facts. We need to help citizens to understand that not all of these messages are true. They are fake news.

4 4 Friends of Europe January 2018 We have to tackle campaigns against vaccination in all countries. We need to help citizens to understand that not all of these messages are true Cristian-Silviu Bușoi Member of the European Parliament Committee on Industry, Research and Energy Another reason for the spread of AMR is the lack of new antibiotics. Colombo noted, It s quite complex to develop new antibiotics but the innovation pipeline is starting to improve. However, at the OECD we estimate that 90 % of funding goes towards the research side. A very small proportion is spent on developing the pull side bringing new products to the market. To address this, the pharmaceutical industry needs to be concrete about what the realistic costs are to develop a new antibiotic so that governments and philanthropic funders can explore where they can support this process financially. INCENTIVES FOR INNOVATION In the past, R&D efforts were hampered by a split between a public sector focussed on public health and a private sector concerned with business, said Lang. We are trying now to move collectively, and we are partnering with public health, Lang continued. You cannot dissociate the research challenges from incentives. AMR is a silent pandemic. It is something that doesn t have a face like Ebola or Zika. It is something that we will all suffer from. It s a global public health emergency and we need to act collectively as responsible, global citizens. In the laboratory, all the low-hanging fruits for antibiotic compounds have already been picked. We now have to aim for fruit that are higher in the trees. This will be more complex. Lang pointed out that there have been only two new classes of antibiotics in the last 30 years. The economic incentives are not there to develop a new drug that would be used as last resort to prevent resistance. The medical industries, such as biotech, diagnostics, generics and research-based pharmaceutical companies, have come together in the AMR Industry Alliance. The Alliance roadmap covers R&D, access, appropriate use of antibiotics and environmental protection. They prioritise investing in R&D to meet public health needs, reducing the development of AMR and improving access to antibiotics, vaccines and diagnostics. A key new incentive for the development of innovative antibiotics is the Transferable Market Exclusivity (TME), said Bușoi. It grants new antibiotic authorisation holders additional months of exclusivity that can help ensure longer term predictability.

5 Coping with antimicrobial resistance Report 5 This new incentive is extremely welcome by developers, underlined Lang. It ensures sustainability for antibiotic and vaccine industries and helps boost innovation. The innovation pipeline is already improving, with new potential drug candidates for future trials. Access is critical, said Lang. In our global work, we can t ignore that antibiotic resistance is hitting lowand middle-income countries very hard. All of our companies have special prices in place and a special environment to encourage the appropriate use of antibiotics in all these countries. You cannot dissociate the research challenges from incentives Jean Lang Associate Vice President at Sanofi Pasteur Research & Development WHAT THE EU IS DOING Since Friends of Europe s first debate on Health Threats, the European Commission has stepped up a gear and issued an AMR action plan in 2017, which explores how EU regulatory tools and incentives could encourage the emergence of novel antimicrobials, particularly where there would not be a guaranteed return on investment. The action plan is also providing funding through the EU Innovative Medicines Initiative (IMI) support for the New Drugs 4 Bad Bugs programme (ND4BB). This brings together industry, academia and biotech organisations to look for solutions to the scientific, regulatory and business challenges that are holding up the development of new antibiotics. Price compared the AMR challenge with that of sustainability and climate change. We can invest and we may get technical solutions, but it s not going to cure things, he said. We can only tackle AMR by behaviour change and by changing the way that our health and agricultural systems use these very precious substances. The EU Commission has produced guidelines on the prudent use of antimicrobials in human health and also guidelines for use in veterinary medicine. Obviously guidelines by themselves don t do anything. It s about the implementation, and that needs to be done through incentives, behaviour change, systems change and support for practitioners. With these words in mind, Friends of Europe aims to publish a factsheet in June 2018 on The One Health Action Plan against AMR, one year after the adoption of the road map by the European Commission. Taking stock of the results achieved so far, this publication will look at what still needs to be done for the EU to fully develop a global approach and enhance multi-sectoral efforts to combat AMR.

6

7 SHARE THE PHOTOS LISTEN TO THE PODCAST

8 Friends of Europe Connect. Debate. Change. Tel: Fax: friendsofeurope.org Friends of Europe is a leading think-tank that connects people, stimulates debate and triggers change to create a more inclusive, sustainable and forward-looking Europe.

Antimicrobial Resistance, yes we care! The European Joint Action Context of the Joint Action General objectives Inclusive governance Conclusion Context of the Joint Action 1. Context of this Joint Action

National Action Plan development support tools Sample Checklist This checklist was developed to be used by multidisciplinary teams in countries to assist with the development of their national action plan

Options for a global development and stewardship framework to combat AMR Consultation of Member States and relevant partners Geneva, 29 February 2016 Peter Beyer Resolution WHA68.7 Requests the to develop

Antimicrobial Stewardship: The South African Perspective Precious Matsoso Director General; National Department of Health; South Africa 13 th November 2015 Why do we need an AMR strategy and implementation

The Third OIE Global Conference on Veterinary Education and the Role of the Veterinary Statutory Body was held in Foz do Iguaçu (Brazil) from 4 to 6 December 2013. The Conference addressed the need for

7 December 2017 Committee for Medicinal Products for Veterinary Use (CVMP) Committee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018 Chairpersons Chair: D. Murphy Status Adopted in December

GHSA Meeting on Step towards Regional Strategic Collaboration in Asia-Pacific on Workforce Development, National Laboratory System Strengthening and Antimicrobial Resistance Prevention to Respond to Global

Impact of NHS England Quality Indicators on Antimicrobial Resistance Professor Alan Johnson National Infection Service Public Health England A Risk Assessment of Antibiotic Pan-Drug Resistance in the UK:

2 nd Joint Conference on the Antimicrobial Resistance Action Plan (AMRAP) and the Strategy for the Control of Antimicrobial Resistance in Ireland (SARI) 1. Background Antibiotic stewardship Implementing

Antimicrobial resistance Summary of OIE Activities July 2015 EDITORIAL Risks associated with the use of antimicrobials in animals worldwide Dr Vallat, Director General of the World Organisation for Animal

Global Conference on Rabies Control: Towards Sustainable Prevention at the Source Seoul (Republic of Korea), 7-9 September 2011 T he World Organisation for Animal Health (OIE) is committed to supporting

Antibiotic Resistance & chicken Chicken Farmers of Canada (CFC) supports the judicious use of antibiotics that have been approved by the Veterinary Drugs Directorate of Health Canada, in order to ensure

Milano, August 31 2015 International Conference Prevention and control of Campylobacter in the poultry production system Dr. Silvio Borrello Direzione generale della sanità animale e dei farmaci veterinari

Control and monitoring of the use of antibiotics as a strategy against antimicrobials resistance Christiane Santiago Maia ANVISA - Brazilian Health Regulatory Agency s Context The burden of deaths from

To protect animal welfare and public health and safety The Dog Meat Trade in Indonesia: A Cruel and Dangerous Trade Every year, millions of dogs are captured and stolen to be transported throughout Indonesia

OIE Collaborating Centre for Animal Welfare Science and Bioethical Analysis An innovative, multi-centre partnership between the New Zealand and Australian Governments and internationally recognised research

Antimicrobial Use and Antimicrobial Resistance in Relation to the Canadian Pork Sector Presented by Jorge Correa Pork Committee Banff May 2013 Part of the Slides were extracted from a Paul Dick presentation

of Conferences of OIE Regional Commissions organised since 1 June 2013 endorsed by the Assembly of the OIE on 29 May 2014 2 12 th Conference of the OIE Regional Commission for the Middle East Amman (Jordan),

PLAYING CHICKEN WITH BUGS AND DRUGS: ANIMAL USE OF ANTIBIOTICS Gail R. Hansen, DVM, MPH Senior Officer The Pew Campaign on Human Health and Industrial Farming The Problem Antimicrobial resistance is one

FMM/RAS/298: Strengthening capacities, policies and national action plans on prudent and responsible use of antimicrobials in fisheries Final Workshop in cooperation with AVA Singapore and INFOFISH 12-14

Mariano Ramos Chargé de Mission OIE Programmes Department Introductory presentation Regional Table Top Exercise for Countries of Middle East and North Africa Tunisia; 11 13 July 2017 Welcome to the Regional

Global Framework for Development & Stewardship to Combat Antimicrobial Resistance Draft Roadmap CONTENTS ABBREVIATIONS... 3 CONTEXT... 4 OBJECTIVES... 4 WHAT DO WE UNDERSTAND BY FRAMEWORK?... 4 HOW DOES

European Medicines Agency Veterinary Medicines and Inspections London, 15 October 2004 EMEA/CVMP/973/04 PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 12 to 14 October 2004

Strategic and Technical Advisory Group on Antimicrobial Resistance (STAG-AMR) Report of Second Meeting 14-16 April 2014 WHO Headquarters, Geneva PANDEMIC AND EPIDEMIC DISEASES WHO/HSE/PED/AIP/2014.4 Strategic

11 December 2014 EMA/CVMP/761582/2014 Veterinary Medicines Division EMEA/V/A/107 Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004

Wageningen Bioveterinary Research Biomedical and veterinary research to safeguard animal and public health Veterinary research to safeguard animal and public health Wageningen Bioveterinary Research (WBVR)

Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite

Veterinary Public Health (VPH) Veterinary Public Health is the application of professional veterinary knowledge, skills and resources to the protection and improvement of human health. VPH plays a fundamental

Antibiotics and beef & lamb Gwyn Jones RUMA Chairman 8 December 2016 Who is RUMA? Unique initiative set up in 1997 Co-ordinated & integrated approach to best practice 25 organisations every stage of farm

ruma RESPONSIBLE USE OF MEDICINES IN AGRICULTURE ALLIANCE GUIDELINES Cattle Responsible use of antimicrobials in Cattle production RUMA guidelines for the responsible use of antimicrobials by cattle farmers

Antibiotic Resistance ACVM information paper Background Within New Zealand and internationally, concerns have been raised about an association between antibiotics used routinely to protect the health of

Office International des Épizooties World Organisation for Animal Health created in 1924 in Paris The Challenge of International Biosecurity and the OIE Standards and Actions Meeting of the State Parties

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health and food audits and analysis DG(SANTE) 2016-8882 - MR FINAL REPORT OF A FACT-FINDING MISSION CARRIED OUT IN DENMARK FROM 01 FEBRUARY

Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network

EurEau s Contribution to the European Commission s Strategic Approach on Veterinary Pharmaceuticals in the Environment Summary Globally, pharmaceutical products are regularly administered to both livestock

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Brussels, 27 February 2018 NOTICE TO STAKEHOLDERS WITHDRAWAL OF THE UNITED KINGDOM AND EU RULES ON ANIMAL HEALTH AND WELFARE AND PUBLIC

12.12.2003 L 325/31 DIRECTIVE 2003/99/EC OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 17 November 2003 on the monitoring of zoonoses and zoonotic agents, amending Council Decision 90/424/EEC and repealing